TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02310997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study: NCT03678688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg OPC-167832
Description: Once daily oral dose of 10 mg OPC-167832 from Day 1 through Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg OPC-167832
Description: Once daily oral dose of 30 mg OPC-167832 from Day 1 through Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90 mg OPC-167832
Description: Once daily oral dose of 90 mg OPC-167832 from Day 1 through Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg OPC-167832
Description: Once daily oral dose of 3 mg OPC-167832 from Day 1 through Day 14.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RHEZ
Description: RHEZ was used in both Stage 1 and Stage 2. Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol. Participants received a single-dose from Day 1 through Day 20. The total number of tablets per day was based on the pretreatment body weight:~* Participants weighing 30 to 37 kg received 2 tablets per day~* Participants weighing 38 to 54 kg received 3 tablets per day~* Participants weighing 55 to 70 kg received 4 tablets per day~* Participants weighing \> 70 kg received 5 tablets per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RHEZ
Description: RHEZ was used in both Stage 1 and Stage 2. Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol. Participants received a single-dose from Day 1 through Day 20. The total number of tablets per day was based on the pretreatment body weight:~* Participants weighing 30 to 37 kg received 2 tablets per day~* Participants weighing 38 to 54 kg received 3 tablets per day~* Participants weighing 55 to 70 kg received 4 tablets per day~* Participants weighing \> 70 kg received 5 tablets per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg OPC-167832 + 300 mg delamanid
Description: Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid from Day 1 through Day 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg OPC-167832 + 400 mg BDQ
Description: Once daily oral dose of 30 mg OPC-167832 plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ
Description: Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
Study: NCT04685395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribamipide gargle \benzdymine HCL gargel
Description: ribamipide gargle 6 time daily 5ml dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribamipide gargle \benzdymine HCL gargel
Description: ribamipide gargle 6 time daily 5ml dosage
Study: NCT05662930

Intervention type: BEHAVIORAL
Intervention: First arithmetic problem solving
Description: In a quiet environment, a white paper in A4 format was placed in front of the patient on the table, and the patients were asked to subtract the number 3 from 2907 for 100 seconds.~The researcher was standing in front of the patient and asks to make corrections by giving a warning whenever the patient made a mistake in the calculation.

Intervention type: BEHAVIORAL
Intervention: First arithmetic problem solving
Description: In a quiet environment, a white paper in A4 format was placed in front of the patient on the table, and the patients were asked to subtract the number 3 from 2907 for 100 seconds.~The researcher was standing in front of the patient and asks to make corrections by giving a warning whenever the patient made a mistake in the calculation.
Study: NCT02130622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Promethazine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Study: NCT01652989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss maintenance intervention face-to-face

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss maintenance intervention delivered via DVD
Study: NCT02806024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drug
Description: 50 cc Normal Saline IV
Study: NCT05379244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-i
Description: Behavioral intervention based on Cognitive Behavioral Therapy for insomnia, adjusted for psychiatric patients with anxiety disorders, affective disorders and trauma
Study: NCT03907657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren lipid microsphere
Description: Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride lipid microspheres
Description: Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
Study: NCT02207712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noctura 400 Eye Mask
Description: The intervention is the wearing of the eye mask

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Standard ranibizumab treatment only
Study: NCT02310997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study: NCT00508612

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Williams LifeSkills Stress and Anger Management Workshop
Description: Williams LifeSkills Stress and Anger Management Workshop

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: High school classes
Description: The control group will attend regular high school classes.
Study: NCT02896270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: The concomitant immunosuppressive regimen is to be reduced at the discretion of the investigators. It is suggested to lower immunosuppressive therapy only in valproic acid target trough levels have been attained.
Study: NCT00975143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIP-Isotretinoin
Description: 0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: 0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
Study: NCT01848847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Study: NCT00581360

Intervention type: DRUG
Group type: OTHER
Intervention: doxorubicin and bortezomib
Description: Patients will be treated with bortezomib 1.3 mg/m2, intravenously on days 1, 4, 8 and 11, and doxorubicin 20 mg/m2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles, if there is no progression, bortezomib once a week at a dose of 1.6 mg/m2 on days 1,8,15, every 28 days, will be administered alone. Treatment will continue unless disease progression or intolerable toxicity emerges.
Study: NCT00574548

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13 valent Pneumococcal Conjugate Vaccine
Description: 0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13 valent Pneumococcal Conjugate Vaccine
Description: 0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13 valent Pneumococcal Conjugate Vaccine
Description: 0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent Pneumococcal Polysaccharide Vaccine
Description: 0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent Pneumococcal Polysaccharide Vaccine
Description: 0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
Study: NCT04018742

Intervention type: OTHER
Intervention: Surgical puncture
Description: Investigators propose to collect 20 abscesses. A collection of abscesses is performed systematically during the diagnostic for bacteriological analysis. There will be no further examination.
Study: NCT01369680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.
Study: NCT02238392

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine test
Description: Testing dormant conduction after PVI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Termination of AF
Description: Testing AF iducibility and ermination of
Study: NCT02529358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standardized text messages
Description: Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies
Study: NCT01484379

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unilateral neck exploration
Description: All elderly patients with primary hyperparathyroidism suspected to have a single gland disease will have a unilateral neck exploration following the index gland identification.
Study: NCT03168100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: taken by mouth
Study: NCT03168100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: administered as a subcutaneous injection
Study: NCT02700165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ CoolSculpting System
Description: The CoolSculpting device will be used to perform the treatments.
Study: NCT02529358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized text messages
Description: Patients write their own messages

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standardized text messages after 10 weeks
Description: Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies which are send to the patients 10 weeks after completing inpatient therapy
Study: NCT00362284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NYUCI-AC
Description: Approximately six individual and family consultation sessions (2 individual, 3 family, 1 individual) within the first 4 months with adult child caregivers and/or their family members; support group participation (recommended at least once a month) after the completion of the individual and family consultation sessions for the duration of the project (up to 3 years after the intake interview); ad hoc consultation (ongoing in-person, telephone, or email support on an as-needed basis) for the duration of the project (up to 3 years after the intake interview); New York University Caregiver Intervention
Study: NCT02574286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velaglucerase alfa
Description: Participants will receive 60-minute intravenous infusion of 60 U/kg velaglucerase alfa EOW.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Participants will receive 800 IU vitamin D orally daily.
Study: NCT03396510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IMPROVED intervention
Description: Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer. If any patient refuses or is unable to complete the symptom assessment on the computer, the investigators will permit them to use paper versions. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden. Patients randomized to IMPROVED will have their symptoms presented to their inpatient oncology team, but the investigators will not provide guidance about what actions to take in response to patients' symptoms.
Study: NCT05847413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Subjects will receive oral verapamil for 12 weeks
Study: NCT01995981

Intervention type: DRUG
Intervention: Pazopanib
Study: NCT04885140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback-based health education
Description: This study was approved by the Tianjin Hospital Ethics Committee, (2019082).The CONSORT 2010 statement: extension to cluster-randomised trials checklist.(Campbell et al., 2012) was used to guide reporting outcomes (File S1).Specific measures have been listed above.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine health education
Description: Routine health education was given to the patients, and the content of health education was the same as that of the experimental group, including the introduction of the disease, clinical manifestations, significance of examination, therapeutic principles of operative methods, psychological nursing, and postoperative rehabilitation exercise, etc. To verify the effect of health education by feedback method.
Study: NCT02578004

Intervention type: OTHER
Intervention: biochemical and molecular analysis

Intervention type: OTHER
Intervention: biochemical and molecular analysis
Study: NCT03137446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous Fluid Cap
Description: Normal Saline or Ringers Lactate limited to 60ml/kg for first 72 hours
Study: NCT06153784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea and Thalidomide
Description: Evaluation of hydroxyurea and thalidomide combination use in beta-thalassemia patients
Study: NCT00863902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine Hydrochloride 10 mg tablets, single dose
Description: A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec® 10 mg tablets, single dose
Description: B: Active comparator Subjects received Pfizer Inc. formulated products under fed conditions
Study: NCT02114099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 10 mg qd x1 year
Study: NCT00750360

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluarixTM
Description: All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluarixTM
Description: All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluarixTM
Description: All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluarixTM
Description: All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluarixTM
Description: All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluarixTM
Description: All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).
Study: NCT03023436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Gastrectomy with D2 lymph node dissection and Metastasectomy for peritoneal metastatic sites only.~A total, distal, or proximal gastrectomy and the type of reconstruction will be selected according to the surgeon's experience.~Metastasectomy is limited to peritoneal metastatic sites only to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: Docetaxel 120 mg diluted in 5.0 L of saline is forced into the abdomen through the inflow catheter by a pump and pulled out through the drains as a heated intraperitoneal perfusion.A heat exchanger keeps the intraperitoneal fluid at 43±0.5℃ and duration limited to 70 minutes.24 hours after cytoreductive surgery no less than 2 cycles postoperative chemotherapy will be recommended.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine
Description: CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
Study: NCT01825759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danshen dripping pill
Study: NCT03370133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab will be provided at pre-specified time intervals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bimekizumab
Description: Bimekizumab will be provided at pre-specified time intervals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: Ustekinumab will be provided as dose 1 for subjects weighing \<=100 kg and as dose 2 for subjects weighing \>100 kg at pre-specified time intervals.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive Placebo at pre-specified time points.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will receive Placebo at pre-specified time points.
Study: NCT02739711

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycoprotein IIb/IIIa inhibitors
Description: Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy
Study: NCT01019733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathecal Autologous Stem Cells
Description: Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 5 times, harvest bone marrow and infused 8 to 10 mL of stem cells (CD34+) by intrathecal via.
Study: NCT02200549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control group
Description: Neither cycle training nor inspiratory muscle training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: calibrated cycle ergometer
Description: The most common device to proform cycle training is calibrated cycle ergometer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: calibrated cycle ergometer and threshold loading device
Description: Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.